The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

Bibliography

• Pan QW, Henry SD, Scholte BJ, New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol 2007;13:4431-6
   PubMed Web of Science ®Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
   PubMedGoogle Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
   PubMed Web of Science ®Google Scholar
• De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007;59:1242-62
   PubMed Web of Science ®Google Scholar
• Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care 2007;13:S319-26
   PubMed Web of Science ®Google Scholar
• Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepatitis 2008;15:2-11
   PubMed Web of Science ®Google Scholar
• Braks RE, Ganne-Carrie N, Fontaine H, Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
   PubMed Web of Science ®Google Scholar
• Tsuda N, Yuki N, Mochizuki K, Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, ; Italian Association of the Study of the Liver Disease (AISF) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Suzuki F, Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007;50:16-23
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Reynaud L, Hemolytic anemia during pegylated interferon alpha 2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 2005;25:283-5
   PubMed Web of Science ®Google Scholar
• Borgia G, Reynaud L, Gentile I, Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C. J Interferon Cytokine Res 2001;21:469-70
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, ; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Borgia F, Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
   PubMed Web of Science ®Google Scholar
• Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13:5673-81
   PubMed Web of Science ®Google Scholar
• Simmonds P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J Gen Virol 2004;85:3173-88
   PubMed Web of Science ®Google Scholar
• Tong X, Bogen S, Chase R, Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antivir Res 2008;77:177-85
   PubMed Web of Science ®Google Scholar
• Perni RB, Almquist S, Byrn RA, Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibithor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909
   PubMed Web of Science ®Google Scholar
• Tong X, Guo Z, Wright-Minogue J, Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 2006;45:1353-61
   PubMed Web of Science ®Google Scholar
• Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-22
   PubMed Web of Science ®Google Scholar
• Summa V. VX-950 (Vertex/Mitsubishi). Curr Opin Investig Drugs 2005;6:831-7
   PubMedGoogle Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Klein C, Chen HJ, Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-7
   PubMedGoogle Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterol 2006;131:997-1002
   PubMed Web of Science ®Google Scholar
• Modi AA, Hoofnagle JH. New therapies for hepatitis C. Hepatology 2007;46:615-17
   PubMed Web of Science ®Google Scholar
• Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004;48:4784-92
   PubMed Web of Science ®Google Scholar
• Lin C, Gates CA, Rao BG, In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Weegink CJ, Antiviral activity of telaprevir (VX-950) and Peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-8
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Miur AJ, Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-9
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Telaprevir with Peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Hèzode C, Forestier N, Dusheiko G, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Berg T, Poordad FF, A study of telaprevir combined with peginterferon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon alfa-2a and ribavirin treatment: interim analysis. Hepatology 2008;48(Suppl):1135-6A
   Google Scholar
• McHutchison JG, Manns MP, Muir A, PROVE 3 final results and 1 year durability of SVR with telaprevir regimen in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Hepatology 2009;50(Suppl):334-5A
   Google Scholar
• Foster GR, Hezode C, Bronowicki JP, Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J Hepatol 2009;50(Suppl 1):S22
   Google Scholar
• Benhamou Y, Moussalli J, Ratziu V, Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 2009;50(Suppl 1):S6
   Google Scholar
• Marcellin P, Forns X, Goeser T, Virological analysis of patients receiving telaprevir administered q8h or 812h with peginterferon-alfa 2a or alfa2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208. Hepatology 2009;50:395A
   Google Scholar
• Antiviral Brief. Advance study begins enrollment. AIDS Patient Care STDs 2008;22:345
   PubMedGoogle Scholar
• HIV/AIDS ans STD Updates. Telaprevir phase 3 Realize trial starts. AIDS Patient Care STDs 2008;22:837
   Google Scholar
• Lòpez-Labrador FX, Moya A, Gonzàlez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 2008;13:481-94
   PubMed Web of Science ®Google Scholar
• Bartels DJ, Zhou Y, Zhang E, Natural prevalence of HCV variants with decreased susceptibility to NS3-4A protease inhibitors in treatment-naive subjects. J Hepatol 2008;48(Suppl 2):S316
   Google Scholar
• Kuntzen T, Timm J, Berical A, Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatol 2008;48:1769-78
   PubMed Web of Science ®Google Scholar
• Cubero M, Esteban JI, Otero T, Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008;370:237-45
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bartels DJ, Hanzelka BL, Phenotypic characterization of resistant Val36 variants of Hepatitis C Virus NS3-4A serine protease. Antimicrob Agents Chemother 2008;52:110-20
   PubMed Web of Science ®Google Scholar
• Welsch C, Domingues FS, Susser S, Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Gen Biol 2008;9:R16
   Web of Science ®Google Scholar
• Lin C, Lin K, Luong YP, In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2004;279:17508-14
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterol 2007;132:1767-77
   PubMed Web of Science ®Google Scholar
• Bartels DJ, Zhou Y, Zhang EZ, Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:800-7
   PubMed Web of Science ®Google Scholar
• McCown MF, Rajyaguru S, Le Pogam S, The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. A step in therapy for hepatitis C. N Engl J Med 2009;360:1899-901
   PubMed Web of Science ®Google Scholar
• Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 2009;30:55-65
   PubMedGoogle Scholar
• Gane EJ, Roberts SK, Stedman CA, Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics and virologic results from INFORM-1. Hepatology 2009;50:394-5A
   Google Scholar